TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9789122

Group type: EXPERIMENTAL
Intervention: MLT plus aloe vera tincture (1 ml twice/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: MLT alone (20 mg/day orally in the dark period)
Number of subjects: 50
Study: 8020904

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunts (TIPS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sclerotherapy (control)
Number of subjects: 30
Study: 2553335

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg 4-times daily
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 0.1 mg 4-times daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo 2 puffs 4-times daily
Number of subjects: 202
Study: 793481

Group type: EXPERIMENTAL
Intervention: Levamisole at a dosage of 2.5 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 30366945

Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (LDRT) - 1 Gray per fraction, administered six times in 2 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (LDRT)
Number of subjects: 55
Study: 30172088

Group type: EXPERIMENTAL
Intervention: Decompressive hemicraniectomy (DHC) without clot evacuation, n = 13
Number of subjects: 30

Group type: COMPARATOR
Intervention: Craniotomy with clot evacuation, n = 17
Number of subjects: 30
Study: 27841912

Group type: EXPERIMENTAL
Intervention: Phosphorylcholine-coated oxygenators
Number of subjects: 20

Group type: COMPARATOR
Intervention: Uncoated oxygenators
Number of subjects: 20
Study: 24568907

Group type: EXPERIMENTAL
Intervention: Huangqi injection (0.5 mL/kg·d for 35 days)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 91
Study: 22777368

Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Uterosacral vault suspension with perioperative pelvic floor muscle training
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Uterosacral vault suspension without perioperative pelvic floor muscle training
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 163
Study: 20220529

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 17927635

Group type: EXPERIMENTAL
Intervention: VUS + CHX chip
Number of subjects: 20

Group type: COMPARATOR
Intervention: VUS alone
Number of subjects: 20
Study: 16054381

Group type: EXPERIMENTAL
Intervention: Protamine administered 5 min after cardiopulmonary bypass
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Protamine administered 35 min after cardiopulmonary bypass
Number of subjects: 30
Study: 12107212

Group type: EXPERIMENTAL
Intervention: r-hCG (5000 IU, 250 microg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: r-hCG
Number of subjects: 40
Study: 10418923

Group type: EXPERIMENTAL
Intervention: Live attenuated human-bovine reassortant rotavirus vaccine (D x UK) - single oral dose (10^5.3 pfu)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Live attenuated human-bovine reassortant rotavirus vaccine (DS-1 x UK) - single oral dose (10^5.8 pfu)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Live attenuated human-bovine reassortant rotavirus vaccine (P x UK) - single oral dose (10^5.8 pfu)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Live attenuated human-bovine reassortant rotavirus vaccine (ST3 x UK) - single oral dose (10^5.8 pfu)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Live attenuated human-bovine reassortant rotavirus vaccine (D x UK) - two doses
Number of subjects: 55
Study: 8562273

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antihypertensive agents
Number of subjects: 0
Study: 2236756

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (12 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhaled salbutamol (200 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 138664

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate containing 60 mg elemental iron twice daily
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg twice daily
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Combination of iron and folic acid
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 30791702

Group type: EXPERIMENTAL
Intervention: Therapeutic songwriting intervention (12-session identity-targeted songwriting programme)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 47
Study: 26846145

Group type: EXPERIMENTAL
Intervention: Usual care plus an educational booklet at discharge with supportive telephone follow‐up on postoperative day 10
Number of subjects: 416

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 416
Study: 26338030

Group type: EXPERIMENTAL
Intervention: Associative learning task with color/shape stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual search task with shape target and irrelevant color distractors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learning experience with predictive color stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocked tasks (Experiment 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tasks on two successive days (Experiment 4)
Number of subjects: 0
Study: 24392555

Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (2.5 mg/0.1 ml)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Topical bevacizumab (2.5%, 25 mg/ml)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sham injection (Control Group B)
Number of subjects: 122
Study: 22118442

Group type: EXPERIMENTAL
Intervention: R-ACVBP (rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)
Number of subjects: 379

Group type: COMPARATOR
Intervention: R-CHOP (rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone)
Number of subjects: 379
Study: 18848413

Group type: EXPERIMENTAL
Intervention: Intensive dietary advice plus information on physical activity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intensive dietary advice
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 16532983

Group type: EXPERIMENTAL
Intervention: Surgical zipper technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional nylon suture
Number of subjects: 50
Study: 14681633

Group type: EXPERIMENTAL
Intervention: Localized subcontractile electrical stimulation on the feet of ischemic limbs for three 60‐minute periods each day over a 6‐week period
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study: 11033396

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK) for myopia correction
Number of subjects: 5936

Group type: EXPERIMENTAL
Intervention: Direct argon-green laser photocoagulation for CNV treatment
Number of subjects: 5936
Study: 9183445

Group type: EXPERIMENTAL
Intervention: Protein Profile of Orientation (PPO)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Classical biological explorations
Number of subjects: 76
Study: 8331618

Group type: EXPERIMENTAL
Intervention: Low-dose insulin infusion (0.25 mU/kg/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose insulin infusion (1.0 mU/kg/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basal and insulin infusion periods
Number of subjects: 0
Study: 3538109

Group type: EXPERIMENTAL
Intervention: Lithium alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lithium and lecithin
Number of subjects: 18
Study: 29754582

Group type: EXPERIMENTAL
Intervention: EC with nicotine
Number of subjects: 10

Group type: COMPARATOR
Intervention: EC without nicotine
Number of subjects: 10
Study: 28915827

Group type: EXPERIMENTAL
Intervention: Guided Walking Program, 6 months duration, 5 times a week, including supervised physical activity and educational sessions
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Adoption data from health center team
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Qualitative data regarding program implementation
Number of subjects: 148
Study: 26030192

Group type: EXPERIMENTAL
Intervention: Neuronox
Number of subjects: 196

Group type: COMPARATOR
Intervention: BOTOX
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 196
Study: 24029556

Group type: EXPERIMENTAL
Intervention: 1-sample OC-Auto® fecal immunochemical test (FIT)
Number of subjects: 2263

Group type: EXPERIMENTAL
Intervention: 2-sample InSure® FIT
Number of subjects: 2263

Group type: EXPERIMENTAL
Intervention: 3-sample guaiac Hemoccult SENSA®
Number of subjects: 2263
Study: 20880171

Group type: EXPERIMENTAL
Intervention: Lafutidine 10 mg administered twice daily for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo administered twice daily for 14 days
Number of subjects: 16
Study: 18248495

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical corticosteroids (standard therapy)
Number of subjects: 50
Study: 17176334

Group type: EXPERIMENTAL
Intervention: Higher transfusion threshold (10 g per dL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower transfusion threshold (7 g per dL)
Number of subjects: 0
Study: 14678131

Group type: EXPERIMENTAL
Intervention: RVOT pacing
Number of subjects: 103

Group type: COMPARATOR
Intervention: RVA pacing
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dual-site RV pacing
Number of subjects: 103
Study: 10854006

Group type: EXPERIMENTAL
Intervention: Lacidipine (4‐6 mg od)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) (25‐50 mg od)
Number of subjects: 15
Study: 8935693

Group type: EXPERIMENTAL
Intervention: Felodipine-ER 5mg/day
Number of subjects: 121

Group type: COMPARATOR
Intervention: Nifedipine-OROS 30mg/day
Number of subjects: 121
Study: 8267872

Group type: EXPERIMENTAL
Intervention: 20% benzocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (80% polyethylene glycol)
Number of subjects: 20
Study: 3885483

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted red cells (Group 2)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Packed red cells (Group 1)
Number of subjects: 107
Study: 30904853

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 0
Study: 29678523

Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived mesenchymal stem cell (ASC) therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27326859

Group type: EXPERIMENTAL
Intervention: Azithromycin-Chloroquine (AZCQ; 250 mg AZ/155 mg CQ base)
Number of subjects: 2891

Group type: COMPARATOR
Intervention: Sulfadoxine-Pyrimethamine (SP; 1,500/75 mg SP QD for 1 day)
Number of subjects: 2891

Group type: EXPERIMENTAL
Intervention: Azithromycin-Chloroquine (AZCQ)
Number of subjects: 2891

Group type: COMPARATOR
Intervention: Sulfadoxine-Pyrimethamine (SP)
Number of subjects: 2891
Study: 25065337

Group type: EXPERIMENTAL
Intervention: HF1 urinary proteomic classifier
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: HF2 urinary proteomic classifier
Number of subjects: 745
Study: 22763083

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 8

Group type: COMPARATOR
Intervention: 7 hours of sleep at night
Number of subjects: 8
Study: 20711566

Group type: EXPERIMENTAL
Intervention: Cued inphase BMT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cued antiphase BMT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repetitive unimanual movement training
Number of subjects: 0
Study: 18588481

Group type: EXPERIMENTAL
Intervention: IC51 (inactivated Japanese encephalitis vaccine)
Number of subjects: 2675

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2675
Study: 16097223

Group type: EXPERIMENTAL
Intervention: Tooth tissue-borne expander (Haas-type)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tooth-borne expander (Hyrax)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both expanders (Haas-type and Hyrax)
Number of subjects: 8
Study: 11817581

Group type: EXPERIMENTAL
Intervention: Tidal irrigation (TI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sham irrigation (SI)
Number of subjects: 180
Study: 11092282

Group type: COMPARATOR
Intervention: NPH insulin therapy
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ultralente insulin therapy
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 79
Study: 9314730

Group type: EXPERIMENTAL
Intervention: Bimanual paradigm with varied shape and size of trajectories for two limbs
Number of subjects: 0
Study: 8340194

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg bid for 5-14 days
Number of subjects: 440

Group type: COMPARATOR
Intervention: Cefadroxil 500 mg bid for 5-14 days
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg qid for ≤ 14 days
Number of subjects: 440

Group type: COMPARATOR
Intervention: Erythromycin 250 mg qid for ≤ 14 days
Number of subjects: 440
Study: 3552457

Group type: EXPERIMENTAL
Intervention: Aqueous lignocaine (5%) spray
Number of subjects: 103

Group type: COMPARATOR
Intervention: Alcoholic lignocaine (5%) spray
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 31197508

Group type: EXPERIMENTAL
Intervention: Resistance training plus photobiomodulation (PBMG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Resistance training (RTG)
Number of subjects: 34
Study: 27151073

Group type: EXPERIMENTAL
Intervention: Body psychotherapy (20 sessions)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Pilates (active control)
Number of subjects: 275
Study: 24721893

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 22935133

Group type: EXPERIMENTAL
Intervention: Pelican intervention in primary care
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Pelican intervention in specialized care
Number of subjects: 270
Study: 20308602

Group type: EXPERIMENTAL
Intervention: PIRR (Peg‐IFN‐alpha + RBV + RTX)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Peg‐IFN‐alpha/RBV
Number of subjects: 37
Study: 18362485

Group type: EXPERIMENTAL
Intervention: Levofloxacin (n = 26)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Doxazosin (n = 26)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combination therapy (n = 29)
Number of subjects: 81
Study: 15948790

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12911202

Group type: EXPERIMENTAL
Intervention: Trachlight (group T)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (group L)
Number of subjects: 26
Study: 10571611

Group type: EXPERIMENTAL
Intervention: Double dose of pantoprazole (2 x 40 mg, Group 2PCA)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Single dose of pantoprazole (40 mg, Group 1PCA)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Both regimens (double and single dose of pantoprazole)
Number of subjects: 192
Study: 8916062

Group type: EXPERIMENTAL
Intervention: Laser flowmeter (LFM) monitoring during craniotomy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control-CBF values
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Laser flowmeter (LFM) monitoring
Number of subjects: 31
Study: 1925193

Group type: EXPERIMENTAL
Intervention: Fixed triple combination (0.05 mg reserpine, 2.5 mg clopamide, 0.4 mg dihydroergocristine)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fixed double combination (0.05 mg reserpine, 2.5 mg clopamide)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fixed triple combination
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fixed double combination
Number of subjects: 34
Study: 31798029

Group type: EXPERIMENTAL
Intervention: sEMG measurement of spinal extensors activity
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Body position during work
Number of subjects: 50
Study: 28027794

Group type: EXPERIMENTAL
Intervention: Intraperitoneal vancomycin, 1g, every 5 days plus oral moxifloxacin, 400mg, every day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intraperitoneal vancomycin, 1g, every 5 days plus intraperitoneal ceftazidime, 1g, every day
Number of subjects: 80
Study: 25863661

Group type: EXPERIMENTAL
Intervention: High-dose recombinant human erythropoietin (rhEpo) 3000 U/kg body weight
Number of subjects: 443

Group type: COMPARATOR
Intervention: NaCl 0.9% (control)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: High-dose recombinant human erythropoietin (rhEpo)
Number of subjects: 443
Study: 23547787

Group type: EXPERIMENTAL
Intervention: Test-informed condition (participants informed that boundary memory would be tested)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non test-informed condition (participants not informed about boundary memory testing)
Number of subjects: 0
Study: 21335616

Group type: EXPERIMENTAL
Intervention: PONI (modular protocol for on-site, nurse-administered intervention)
Number of subjects: 163

Group type: COMPARATOR
Intervention: EUC (enhanced usual care)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: PONI
Number of subjects: 163

Group type: COMPARATOR
Intervention: EUC
Number of subjects: 163
Study: 19519256

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Number of subjects: 202
Study: 17530098

Group type: EXPERIMENTAL
Intervention: Off-pump technique
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: On-pump beating-heart technique
Number of subjects: 45
Study: 15385352

Group type: EXPERIMENTAL
Intervention: Electro-acupoint stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sham control)
Number of subjects: 0
Study: 11293559

Group type: EXPERIMENTAL
Intervention: 100-mg sumatriptan tablets
Number of subjects: 231

Group type: COMPARATOR
Intervention: 50-mg sumatriptan tablets
Number of subjects: 231
Study: 9674377

Group type: EXPERIMENTAL
Intervention: Dynamometer testing for peak force (PF) in the sagittal plane
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dynamometer testing for isometric strength (IS) at 90 degrees to the lateral plane
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ratings of perceived exertion for low back and right arm in isometric lifting
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Test-retest reliability of dynamic forces in the dynamometer
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isometric strength in the sagittal plane
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isometric strength at right angles to the lateral plane
Number of subjects: 13
Study: 8083076

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (200 U/kg/day) and ferrous sulfate 5‐10 days prior to initiation of external beam radiation therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ferrous sulfate alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 20
Study: 2754150

Group type: EXPERIMENTAL
Intervention: 4.5% saline nebulization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocapneic hyperventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased dose of 4.5% saline via higher output nebulizer
Number of subjects: 0
Study: 55650

Group type: EXPERIMENTAL
Intervention: Lippes Loop
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Dalkon Shield
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Copper 7
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Dalkon Shield (small size) for nulliparae
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Copper 7 for nulliparae
Number of subjects: 279
Study: 31113007

Group type: EXPERIMENTAL
Intervention: GLICEMIA intervention (3 individual counseling sessions and 5 group-based lectures)
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: GLICEMIA intervention
Number of subjects: 1087

Group type: COMPARATOR
Intervention: Control group (reduced standard information)
Number of subjects: 1087

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1087
Study: 31005385

Group type: EXPERIMENTAL
Intervention: Levetiracetam (40 mg/kg over 5 min)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Phenytoin (20 mg/kg over at least 20 min)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 286

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 286
Study: 28065961

Group type: EXPERIMENTAL
Intervention: Deep cross-friction massage for 30 minutes, 5 times a week for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine physiotherapy (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Deep cross-friction massage
Number of subjects: 60
Study: 25811584

Group type: EXPERIMENTAL
Intervention: 50% inhaled oxygen
Number of subjects: 46

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 46
Study: 23789452

Group type: EXPERIMENTAL
Intervention: hilifox‐750 (750 mg daily for 5 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: amoxiclav (875/125 mg twice daily for 10 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: hilifox‐750
Number of subjects: 60
Study: 20696676

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin-docetaxel (D 75 mg/m² on day 1 and C 40 mg/m² on days 1 and 2) followed by concurrent chemoradiotherapy (66 Gy with weekly D 20 mg/m² and C 20 mg/m²)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Consolidation chemotherapy with cisplatin-docetaxel (D 75 mg/m² on day 1 and C 40 mg/m² on days 1 and 2) followed by concurrent chemoradiotherapy (66 Gy with weekly D 20 mg/m² and C 20 mg/m²)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Consolidation chemotherapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 70